Business Wire

LatticeFlow AI Acquires AI Sonar, the Leading AI Discovery Platform, to Enable End-to-End, Secure AI Governance

21.1.2026 08:22:00 CET | Business Wire | Press Release

Share

LatticeFlow AI, a Swiss deep-tech company leading evidence-based AI governance, today announced during the World Economic Forum (WEF) the acquisition of Dublin-based AI Sonar Ltd, a wholly owned subsidiary of CloudSphere Ltd. AI Sonar’s leading edge AI discovery platform allows enterprises and ISVs to detect shadow AI. AI Sonar’s solution will continue to be offered under its brand name by LatticeFlow AI.

With this acquisition, LatticeFlow AI will introduce the industry’s first end-to-end, evidence-based AI governance solution securely connecting on-prem AI discovery and evaluations with centralized SaaS governance operations, and covering GenAI, agentic and traditional AI systems.

As part of the acquisition, LatticeFlow AI assumes full ownership of AI Sonar’s platform, intellectual property, and engineering operations, establishing Dublin as its third R&D office alongside Zurich, Switzerland and Sofia, Bulgaria. The AI Sonar engineering team will continue the development of this enterprise-grade AI discovery platform, with full integration into LatticeFlow AI’s product roadmap. CloudSphere’s former CTO, Paul Mansfield, will join LatticeFlow and lead the combined engineering group.

Establishing AI Discovery as a Critical Layer for Enterprise AI Governance

With this acquisition, LatticeFlow AI establishes AI discovery as a foundational capability for AI governance at scale, addressing the shift from a handful of AI deployments to hundreds of thousands. AI Sonar can automatically identify AI assets, maintaining a continuously updated enterprise AI catalogue, and linking each asset to the evidence generated through LatticeFlow AI’s technical evaluations.

“AI governance cannot work without visibility,” said Dr. Petar Tsankov, CEO and Co-Founder of LatticeFlow AI. “This acquisition reinforces our leadership in evidence-based AI governance by making clear that AI governance is a technical discipline, much like cybersecurity, and must be embedded directly into the technology stack, not managed through paper checklists or dashboards. With AI Sonar, we can scan both on-prem and cloud environments to discover AI systems and govern them end-to-end, securely, privately, and at scale.”

Why AI Discovery Matters Now

AI adoption is outpacing governance. As AI systems are rapidly embedded across enterprise applications, including by software vendors and through employee use, organizations are managing increasingly complex AI environments, often without a complete and continuously updated view of where AI systems are deployed or how they operate.

This growing lack of visibility creates material risk. Organizations struggle to maintain accountability, enforce consistent controls, and protect sensitive data. Security, compliance, and legal teams are left reacting to issues after deployment, rather than governing AI proactively as part of its lifecycle.

AI discovery addresses this challenge by establishing continuous visibility across the entire AI estate. By automatically identifying AI systems across on-prem and cloud environments, organizations gain a reliable, always-up-to-date inventory of their AI assets. This foundation enables consistent governance, risk, and compliance controls, and supports live, evidence-based assessments as AI systems evolve.

Advancing AI Governance. Done Right.

With this acquisition, LatticeFlow AI will extend its AI governance stack across the AI lifecycle, from AI discovery and cataloguing to technical risk assessments, evidence generation, and continuous monitoring, allowing:

- Fully private and secure AI governance, connecting on-prem AI discovery and evaluations with centralized, SaaS governance operations.

- Live AI portfolio discovery across cloud and on-prem AI systems.

- End-to-end AI governance workflows, connecting discovery, governance frameworks, and deep technical controls.

Looking ahead, LatticeFlow AI will continue expanding AI governance capabilities aligned with enterprise security, and regulatory requirements, supporting organizations as AI adoption accelerates in scale and complexity.

About LatticeFlow AI

LatticeFlow AI sets a new standard in AI governance through deep technical assessments that enable evidence-based decisions and empower enterprises to accelerate AI adoption with confidence. As the creator of COMPL-AI, the world’s first EU AI Act framework for Generative AI developed with ETH Zurich and INSAIT, the company combines Swiss precision with scientific rigor to operationalize AI governance built on evidence and trust.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260120658195/en/

Contacts

Media Enquiries:
Gloria Fernandez, Marketing Director
media@latticeflow.ai
LatticeFlow AI

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye